Adair Jason sold $562K of LQDA

Adair Jason (Chief Business Officer) sold 7,863 shares of Liquidia Corp (LQDA) at an average of $71.51 ($71.39–$71.52, $0.56M total) across 2 trades on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Adair Jason
Published Jul 15, 2026, 12:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 15, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
high confidence
Mentioned
$LQDA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider selling activity (size, price range, and 10b5-1 status) but does not introduce new fundamentals like earnings, guidance, trial results, or regulatory actions.

02

Market read

Useful for monitoring insider behavior, but unlikely to drive a durable repricing without additional company-specific catalysts.

03

What to watch

Traders may over-weight insider selling; the key missing context is whether other insiders also sold/bought around the same window and whether the company has concurrent fundamental catalysts.

Relevance 4/10Novelty 3/10Timing: after-hours filing update on 2026-07-14 for a 2026-07-13 sale

Background

The article is a SEC Form 4 insider transaction disclosure for Liquidia Corp, reported by CBO Adair Jason.

Company-level read

Ticker impact

$LQDANeutralHigh confidence
Context

Liquidia Corp disclosed an insider open-market sale by CBO Adair Jason of 7,863 shares at about $71.51 on a 10b5-1 plan.

Expected impact

Likely limited near-term price impact; any reaction would be sentiment-driven rather than earnings or guidance-related.

Evidence & confidence

The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan and no accompanying operational or financial disclosure.

Market effects

No clear sector read-through because the disclosure is an individual insider sale without new company guidance or clinical/regulatory updates.

None.

None.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may not reflect new negative information and could be mechanically scheduled.

Key entities

  • Liquidia Corp

    Company whose insider transaction was reported on Form 4.

  • Adair Jason

    Chief Business Officer who sold shares in an open-market transaction under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.